Back to search results

Collecting Biospecimens for Cancer Research

This observational study, called the Texas Immuno-Oncology Biorepository (TIOB), aims to collect and store samples like tissue, blood, urine, and stool from people with cancer. These samples will come from patients receiving standard surgeries or FDA-approved immunotherapy treatments. The goal is to create a large collection of samples and medical information from a diverse group of patients across Texas. This collection will help researchers better understand how cancer works and how different treatments, especially immunotherapy, affect patients over time. The study plans to enroll up to 10,000 participants. You may be able to join if you are over 18 and are suspected of having cancer or have a confirmed cancer diagnosis.

Study design
This is an observational study, meaning researchers will collect information and samples without providing any specific intervention. It aims to enroll up to 10,000 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary goal is to develop a biorepository, measured at 15 years, which suggests long-term collection of samples and data.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05371756

The TIOB - Collection of Patients' Biospecimens for Analysis of Immunological and Molecular Biomarkers.

Recruiting
Not specifiedAges 18+Observational
Baylor Research Institute
~10,000 participants
Updated 2026-03-16 on ClinicalTrials.gov

At a glance

Recruiting sites
8 of 8 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Develop a biorepository
Measured over 15 years

Conditions

Cancer

Explore related trials

Malignant Neoplasm

Where it's being run

8 sites across 1 states
Texas8

Study leadership

  • Ronan J Kelly, MD, MBA · PRINCIPAL_INVESTIGATOR · Baylor Scott & White Research Institute

Who to contact

Pukar Ratti, MSChE, MSHCM
[email protected]
214-818-8472
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Participant is over 18 years of age at the time of signing the informed consent form.
Participant is able and willing to sign an informed consent form.
Participant is suspected by a provider of being at risk for developing cancer,
Participant has confirmed or clinically suspected malignancy by a provider. This includes but is not limited to:

Exclusion

Participant is unable or unwilling to donate blood.
Concurrent medical or psychiatric condition or disease that may compromise the ability to give documented informed consent, is likely to interfere with study procedures or results, or that in the opinion of the investigator would constitute a hazard for participating in this study.

What this trial measures

  • Develop a biorepository15 years

    Develop a biorepository that ensures molecular integrity and clinical relevance of quality human biospecimens and associated patho-clinical data for development of new diagnostic and therapeutic technology.